Penumbra Inc
No enriched coverage for $PEN in the last 7 days.
No SEC Form 4 filings for $PEN in the last 30 days.
See all $PEN insider activity →Boston Scientific (BSX) rose 2.03% to $50.37 on Friday, recovering 38% of Thursday's loss. The stock's weekly decline was 2.82%. Analysts forecast 24.46% upside, with 26 of 31 rating it Buy or Strong Buy. The company reported Q2 sales of $5.442 billion, up 7.5%, but lowered full-year EPS guidance. It plans a $14.5 billion acquisition of Penumbra (PEN).
Panoro Energy ASA will acquire a 9.09% interest in Block CI-27 offshore Côte d’Ivoire from DNO ASA for $80M. The asset has 3,287 boepd production and 9.4 MMboe reserves. Panoro aims to boost production and reserves, financing the deal with equity and debt.
Penumbra Inc (PEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2026 Financial Results ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026. • Revenue of
Recent PEN coverage spans earnings, technology and financial news.
The announced acquisition creates upside potential for Penumbra shareholders at the deal price, but execution risk remains.
Accretive acquisition increasing production and reserves; potential upside from new country entry.
Q2 results show continued growth and strong gross margin, but the key trading variable is the acquisition-driven removal of full-year guidance.
Positive clinical readout for Penumbra’s THUNDERBOLT CAVT system, supporting safety and effectiveness claims in ELVO stroke.
The article frames a sharp, unexplained intraday selloff for PEN, with key overhangs including prior dilution, funding, and a court-related suspension.
AlphAI scores every news story that mentions PEN with an AI model for sentiment and relevance, and aggregates insider trades from Penumbra Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Boston Scientific (BSX) rose 2.03% to $50.37 on Friday, recovering 38% of Thursday's loss. The stock's weekly decline was 2.82%. Analysts forecast 24.46% upside, with 26 of 31 rating it Buy or Strong Buy. The company reported Q2 sales of $5.442 billion, up 7.5%, but lowered full-year EPS guidance. It plans a $14.5 billion acquisition of Penumbra (PEN).
2 min readPanoro Energy ASA will acquire a 9.09% interest in Block CI-27 offshore Côte d’Ivoire from DNO ASA for $80M. The asset has 3,287 boepd production and 9.4 MMboe reserves. Panoro aims to boost production and reserves, financing the deal with equity and debt.
2 min readPenumbra Inc (PEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2026 Financial Results ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026. • Revenue of
4 min readPenumbra (NYSE: PEN) reported THUNDER IDE study results for its THUNDERBOLT computer-assisted vacuum thrombectomy system in emergent large vessel occlusion stroke. In 216 patients, 87.5% achieved mTICI 2b-3 reperfusion, with median time-to-revascularization of 20 minutes and 2.8% device/procedure-related serious adverse events. FDA clearance and CE Mark were noted.
4 min readPeninsula Energy Limited (ASX:PEN) shares fell about 26.03% intraday on 22 July 2026, according to a market snapshot. The company operates the Lance ISR uranium project in Wyoming and reaffirmed 2026 guidance of 400,000 to 500,000 lb U3O8 and 2027 guidance of 500,000 to 600,000 lb. In May 2026 it secured about US$56m funding. No specific disclosure was identified for the exact move.
7 min readPenumbra said the FDA cleared its Thunderbolt computer-assisted vacuum thrombectomy device for acute ischemic stroke, aimed at distal occlusions. Thunderbolt uses modulated aspiration with standard aspiration to help remove clots more completely. IDE study results will be presented in July, and Penumbra also reported a CE Mark and starting the Forward study.
4 min readPennant International Group plc (AIM: PEN) said it has made its first sale of Auxilium–GenS via its Siemens partnership to a North American digital engineering customer supporting defence, national security and space missions. The sale follows a July 2025 agreement under which Siemens Digital Industries Software is licensed to distribute Auxilium–GenS through its Teamcenter platform.
4 min readPenumbra Inc (PEN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. pen-20260618 0001321732 FALSE 0001321732 2022-06-01 2022-06-01 __________________________________________________________________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________
2 min readVanguard Capital Management has reported a beneficial ownership of 1,990,629 shares in Penumbra Inc. (NYSE: PEN), which represents a 5.07% stake. This information is disclosed in a Schedule 13G SEC filing, indicating Vanguard's passive investment intentions. The filing details Vanguard's sole dispositive power over all 1.99 million shares and sole voting power over 296,141 shares, signed by Ashley Grim.
2 min readPenumbra has announced its 2026 annual stockholder meeting for June 18, 2026, where shareholders will vote on director elections, auditor ratification, and executive compensation. A separate special meeting will address the proposed $14.5 billion acquisition by Boston Scientific Corporation, valuing Penumbra shares at $374 each, with consideration split between cash and Boston Scientific stock. The proxy statement details the financial terms of the merger and outlines the company's executive compensation philosophy, which emphasizes base salary and long-term equity awards.
4 min read
